Privia Health Group (NASDAQ:PRVA) Issues Quarterly Earnings Results

Privia Health Group (NASDAQ:PRVA) posted its quarterly earnings results on Thursday. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.08 by $0.11, FiscalAI reports. Privia Health Group had a net margin of 0.97% and a return on equity of 2.81%. The company had revenue of $603.85 million for the quarter, compared to analyst estimates of $560.99 million. During the same period in the prior year, the company earned $0.22 earnings per share. The firm’s revenue was up 25.8% on a year-over-year basis.

Here are the key takeaways from Privia Health Group’s conference call:

• Provider and attribution growth: Implemented providers reached 5,535 (+13.6% YoY) and attributed lives hit 1.6M (+26.5% YoY), driving practice collections up 14.6% to $914.8M and providing visible revenue runway for 2026.
• Profitability expansion: Adjusted EBITDA rose 36.3% to $36.7M with EBITDA representing 28.5% of care margin (up 290 bps), and management expects ~20% EBITDA growth at the midpoint of guidance with ~80% conversion to free cash flow.
• Strong balance sheet and reiterated guidance: Ended Q1 with $419.5M cash and no debt, maintained full-year 2026 guidance (raising only attributed-lives range), and signaled capacity to fund organic growth and disciplined M&A.
• M&A and integration progress: The Evolent ACO assets are reported ahead of integration schedule, management says the business-development pipeline is robust and will be used to expand Privia’s multi-state footprint.
• Technology and AI focus: New CTO hire and a push to deploy generative AI across enterprise, care-center, and care-delivery workflows are expected to boost productivity and help push margins toward the high end of long-term targets.

Privia Health Group Stock Down 3.7%

PRVA traded down $0.90 on Friday, reaching $23.10. The company had a trading volume of 1,080,445 shares, compared to its average volume of 972,100. Privia Health Group has a 1 year low of $18.77 and a 1 year high of $26.51. The stock has a market capitalization of $2.90 billion, a PE ratio of 144.35, a P/E/G ratio of 1.50 and a beta of 0.96. The stock has a 50-day moving average price of $22.73 and a 200-day moving average price of $23.34.

More Privia Health Group News

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Privia Health reported first-quarter results that beat revenue expectations, with sales of $603.85 million versus the $560.99 million estimate, and EPS of $0.19 versus $0.08 expected. The company also said revenue rose 25.8% year over year, and it reiterated full-year 2026 guidance. Article Title
• Positive Sentiment: The company’s updated 2026 outlook calls for revenue of $2.4 billion to $2.5 billion, which is in line with or slightly above market expectations and supports the case for continued growth. Article Title
• Neutral Sentiment: Investors are also parsing the Q1 2026 earnings call transcript and related earnings coverage for management commentary on margins, utilization trends, and the path to hitting full-year targets. Article Title
• Negative Sentiment: Two insider-selling reports may be weighing on sentiment: the CFO sold about $179,690 of stock and a director sold about $427,229 of stock, which can signal caution even when fundamentals are improving. Article Title Article Title

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PRVA. Truist Financial increased their target price on shares of Privia Health Group from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Jefferies Financial Group reiterated a “buy” rating and issued a $32.00 price objective on shares of Privia Health Group in a report on Thursday, February 26th. Barclays raised their price target on shares of Privia Health Group from $23.00 to $25.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 25th. Canaccord Genuity Group decreased their target price on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Citigroup lowered their target price on shares of Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Privia Health Group currently has an average rating of “Moderate Buy” and an average price target of $31.23.

Insider Activity at Privia Health Group

In other Privia Health Group news, Director Matthew Shawn Morris sold 1,017 shares of Privia Health Group stock in a transaction on Monday, May 4th. The shares were sold at an average price of $24.96, for a total value of $25,384.32. Following the transaction, the director directly owned 68,188 shares in the company, valued at approximately $1,701,972.48. The trade was a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO David Mountcastle sold 1,206 shares of Privia Health Group stock in a transaction on Monday, May 4th. The shares were sold at an average price of $25.00, for a total transaction of $30,150.00. Following the completion of the transaction, the chief financial officer owned 214,847 shares in the company, valued at approximately $5,371,175. This represents a 0.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 274,255 shares of company stock valued at $6,299,092 over the last ninety days. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Durable Capital Partners LP increased its stake in shares of Privia Health Group by 1.8% during the third quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company’s stock worth $291,123,000 after acquiring an additional 203,842 shares during the period. State Street Corp increased its stake in shares of Privia Health Group by 1.5% during the second quarter. State Street Corp now owns 4,171,069 shares of the company’s stock worth $95,935,000 after acquiring an additional 61,853 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Privia Health Group by 6.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,264,038 shares of the company’s stock worth $53,682,000 after acquiring an additional 128,415 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Privia Health Group by 2.7% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,165,355 shares of the company’s stock worth $53,917,000 after buying an additional 55,944 shares during the period. Finally, Franklin Resources Inc. grew its position in Privia Health Group by 19.1% during the third quarter. Franklin Resources Inc. now owns 1,596,634 shares of the company’s stock worth $39,756,000 after buying an additional 256,236 shares during the period. 94.48% of the stock is currently owned by institutional investors and hedge funds.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.